Stem Cell Study for Patients With Heart Failure

Inclusion Criteria:

• Subjects greater than 21 years old.

• Subjects with functional class (NYHA) III ischemic heart failure.

• Subjects who have attempted "best" cardiac medical therapy including long-actingnitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-convertingenzyme inhibitors without control of symptoms.

• Subjects must be identified as non-candidates for conventional revascularization bytheir referring cardiologist. The patient's angiogram will then be reviewed by anindependent interventional cardiologist and independent cardiac surgeon to determineif the patient is eligible for revascularization.

• Subjects must have left ventricular ejection fraction <40% by echocardiography.

• All subjects must have a recent coronary angiogram (within the last 1 year) todocument the coronary anatomy and insure the presence of coronary disease that is notamenable to standard revascularization procedures.

• Have serum B-type Natriuretic Peptide (BNP) level >100 pg/ml.

Exclusion Criteria:

• Myocardial infarction (Q wave or non-Q wave defined as CKMB >3 times normal) within 30days of treatment.

• Successful coronary revascularization procedures within 3 months of study enrollment.

• Documented stroke or transient ischemic attack (TIA) within 60 days of studyenrollment.

• NYHA Class I, II or IV heart failure and patients with idiopathic or non-ischemicheart failure.

• History of severe aortic stenosis (aortic valve area < 1.0 cm2) or insufficiency (>2+); severe mitral stenosis (mitral valve area <1.5 cm2); or severe mitralinsufficiency(>2+).

• Implantation of biventricular pacemaker within 90 days of study treatment.

• Severe co-morbidity associated with a reduction in life expectancy of less than 1year, such as chronic medical illness (i.e. severe chronic obstructive pulmonarydisease, renal failure or cancer).